Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 25Terminated 8Active not recruiting 6Recruiting 5Unknown 3Withdrawn 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6

Conditions

Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 37Lung Neoplasms 27Triple Negative Breast Neoplasms 25Ovarian Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Fallopian Tube Neoplasms 16Small Cell Lung Carcinoma 15Neoplasm Metastasis 14Endometrial Neoplasms 13Esophageal Neoplasms 11Neoplasms 10Prostatic Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Laryngeal Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Stomach Neoplasms 4Mouth Neoplasms 4Melanoma 4Carcinoma, Ovarian Epithelial 4Urothelial Cancer 3

Interventions

Rituximab 32Cyclophosphamide 28Lenalidomide 19Prednisone 16Doxorubicin 16Vincristine 14Etoposide 11CT-P10 11Gemcitabine 9polatuzumab vedotin 8Oxaliplatin 7ibrutinib 6glofitamab 6fludarabine 6acalabrutinib 6Magnetic Resonance Spectroscopy 6Ifosfamide 6Carboplatin 6tafasitamab 5prednylidene 5pembrolizumab 5obinutuzumab 5deltacortene 5Specimen Handling 5R-CHOP protocol 5Nivolumab 5Biopsy 5venetoclax 4fludarabine phosphate 4selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large B-Cell, Diffuse × Carboplatin × Clear all
NCT04663347 2026-06-02

EPCOREâ„¢ NHL-2

Genmab

Phase 1/2 Active not recruiting
543 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05221645 2026-05-15

P+R-ICE

University of Southampton

Phase 2 Active not recruiting
65 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01959698 2026-01-28

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Roswell Park Cancer Institute

Phase 1 Active not recruiting
29 enrolled 19 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04833114 2025-09-30

Pola-R-ICE

GWT-TUD GmbH

Phase 3 Active not recruiting
306 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04665765 2025-09-03

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2 Active not recruiting
41 enrolled 12 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02628405 2024-07-01

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Academic and Community Cancer Research United

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡